Detalles de la búsqueda
1.
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
Br J Haematol
; 189(4): 689-693, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31994178
2.
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL.
Leuk Lymphoma
; 58(7): 1598-1606, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27830957
3.
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
Leuk Lymphoma
; 58(5): 1084-1093, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27731748
4.
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
Leuk Lymphoma
; 57(9): 2037-46, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26784000
5.
A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial.
Leuk Lymphoma
; 61(7): 1748-1751, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107948
Resultados
1 -
5
de 5
1
Próxima >
>>